Asset profile
GR-MD-02
Protein / enzyme therapeutic
Evidence outlook · lead readout
NCT02421094 · Nonalcoholic Steatohepatitis
The lead readout missed its primary endpoint. The grade and rationale below record what the trial was designed to show and what it found.
NCT02421094: The trial was randomized, quadruple-blind, and placebo-controlled, but included only 30 participants. Its primary endpoint was a surrogate MRI biomarker rather than a clinical or endoscopic outcome, and the comparison was not statistically significant (p=0.1621), so the findings provide limited evidence of benefit.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.